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Plasma viremia during HIV-1 infection is regulated by a dynamic balance between viral replication and removal of infected
cells and cell-free virus. Administration of novel potent antiretroviral drugs provides an opportunity to study the consequences
of perturbing this equilibrium by blocking de novo infections. In this study, we examined the expression of differentially
spliced forms of HIV-1 mRNA, unspliced (US) and multiply spliced (MS), in peripheral blood mononuclear cells (PBMCs) of
patients treated with HIV protease inhibitors or combination therapy. In all nine patients studied, a significant reduction in
the MS/US mRNA ratio was observed after 1 week of treatment, suggesting that the majority of HIV MS mRNA in the
steady-state situation prior to therapy was expressed by cells which had been infected during the previous couple of days.
This idea was supported by a detailed analysis of serial PBMC specimens collected from two of the patients during the
first hours and days after initiation of therapy. In both cases, a substantial decrease in MS mRNA expression was evident
already after 48 hr, whereas the expression of US mRNA at this time was virtually unaffected. These data indicate that the
HIV mRNA splicing pattern in vivo is mainly determined by the relative proportion of newly infected cells and suggest that
examination of this pattern could be useful in evaluating the potency of antiretroviral therapies and in studying dynamics
of HIV-1 infection. q 1997 Academic Press
Cullen, 1994; Pavlakis et al., 1991; Pavlakis and Felber,INTRODUCTION
1990).
Differential splicing of HIV-1 RNA generates more than HIV-1 mRNA splicing has also been studied in vivo
30 distinct mono- or bicistronic mRNA species which fall using reverse transcription-initiated polymerase chain re-
into three classes: the unspliced (US) full-length 9-kb action (RT-PCR) techniques. Intriguingly, an early study
mRNA, partially spliced 4- to 5-kb mRNAs, and the multi- reported a dramatic overexpression of MS RNA relative
ply spliced (MS) 2-kb mRNAs (Neumann et al., 1994; to US mRNA in peripheral blood mononuclear cells
Schwartz et al., 1990, 1992; Pavlakis et al., 1991). US (PBMCs) of most asymptomatic (but not symptomatic)
mRNA encodes the Gag and Gag-Pol polyproteins, and subjects, suggesting that clinical latency of HIV infection
also serves as the genomic RNA of progeny virions. MS is associated with a ‘‘blocked early-stage’’ HIV mRNA
mRNAs give rise to the regulatory and accessory HIV splicing pattern, as if the viral life-cycle in these cells
proteins Tat, Rev, Nef, Vpr, and Vif. was arrested in an early postintegration step (Seshamma
Kinetic analyses of HIV mRNA expression in vitro in et al., 1992). Although similar results have not been ob-
newly infected cells (Kim et al., 1989; Klotman et al., 1991; served in other studies, some recent reports have also
Ranki et al., 1994) and in activated latently infected cells suggested that HIV-1 mRNA splicing pattern in PBMC
(Michael et al., 1991; Pomerantz et al., 1990) have re- could be of clinical significance, and indicated an associ-
vealed a temporal pattern of mRNA splicing consisting ation between a reduced MS/US ratio and a poor progno-
of early expression of mostly MS mRNA which changes sis (Furtado et al., 1995; Michael et al., 1995).
during the subsequent 12–48 hr to a predominance of Our longitudinal studies on a large HIV-1-infected co-
US mRNA. This process has been attributed to increasing hort have not provided support for this hypothesis. We
levels of the Rev protein which binds to US and partially found that while the overall HIV mRNA expression
spliced mRNAs containing a Rev-responsive element strongly correlated with prognosis, MS and US mRNAs
and is required for efficient accumulation of these were expressed in roughly equimolar ratios in PBMCs
mRNAs in the cytoplasm of infected cells (reviewed in of most asymptomatic individuals regardless of the sub-
sequent course of their disease (Saksela et al., 1994,
1995; Vesanen et al., 1996). Similar findings were recently
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elli et al., 1996). Furthermore, in cases when we have onto ice, and combined with a mixture containing: 6 ml
51 reaction buffer (51: 250 mM Tris, pH 8.3; 375 mMfound the MS/US ratio to significantly deviate from 1:1,
no association with a particular future disease pattern KCl, 15 mM MgCl2), 1.5 ml dNTPs 10 mM each, 0.6 ml
RNasin, 1 ml random hexamers (1 mM, Pharmacia), andhas been observed. Similar to the studies by Michael et
al. and Furtado et al., however, we (Saksela et al., 1994; 2 ml M-MLV-reverse transcriptase (200U/ml; Gibco-BRL)
and incubated for 1 hr at 427.Vesanen et al., 1996) and others (Saltarelli et al., 1996)
have noticed a relative loss of MS mRNA in PBMCs of
Amplification of US HIV-1 mRNAsome individuals upon development of CD4/ T lympho-
penia. The underlying causes of such aberrant HIV Two-microliters of random-primed PBMC cDNA was
mRNA splicing patterns are yet to be elucidated. added into each 50 ml PCR reaction containing 10 mM
Recent studies on patients treated with novel potent Tris, pH 8.5, 50 mM KCl, 1.0 mM MgCl2 , 0.02% gelatin,
antiretroviral drugs have shown that the viral load in 50 mM of each unlabeled dNTPs, 150 ng each oligonucle-
plasma of infected individuals is determined by a highly otide primer, 0.25 ml a[32P]dCTP (NEN, 3000 Ci/mmol),
dynamic equilibrium between HIV production and clear- and 0.25 ml Taq-polymerase (5 U/ml; Boehringer Mann-
ance (Ho et al., 1995; Wei et al., 1995). Moreover, it has heim). These reactions were cycled for 31 rounds be-
been shown that the rapid decline in plasma viremia tween 94 (40 sec) and 697 (1 min) using Perkin–Elmer
results from the decay of two components: removal of GeneAmp PCR system 9600. The primers used for US
productively infected cells (T1/2  1.6 days) and clear- HIV-1 mRNA amplification were: 5*-TCT CTA GCA GTG
ance of cell-free virus (T1/2 6 hr) (Perelson et al., 1996). GCG CCC GAA CA-3* (sense) and 5*-TCT CCT TCT AGC
Thus, it can be concluded that approximately half of the CTC CGC TAG TC-3* (antisense) giving rise to a 160-
productively infected PBMCs at any given time have be- bp product. This assay detects full-length HIV-1 mRNA
come infected as recently as during the preceding 2 encoding Gag and Gag-Pol proteins as well as genomic
days. HIV RNA.
Therefore, assuming that the temporal changes in HIV
mRNA splicing pattern that occur in vivo are similar to Amplification of MS HIV-1 mRNA
those seen in vitro (Kim et al., 1989; Klotman et al., 1991;
MS HIV-1 mRNA was amplified using a nested PCRMichael et al., 1991; Pomerantz et al., 1990; Ranki et
strategy. Both rounds of amplification were done usingal., 1994), it is predicted that in a steady-state situation,
the same reaction conditions as described for US mRNAexpression of viral MS mRNA relative to US mRNA would
and utilized a common antisense primer: 5*-TTC CTTbe determined by the proportion of recently infected cells
CGG GCC TGT CGG GTC GG-3*. The sequence of theamong all circulating productively infected cells, and that
outer sense MS primer was 5*-CTT AGG CAT CTC CTAblocking infection of new cells by potent antivirals should
TGG CAG GAA-3*, and the inner one was 5*-TCC TATresult in a rapid decrease in the MS/US mRNA ratio.
GGC AGG AAG AAG CGG AG-3* (resulting in fragmentsThe present results provide experimental data to directly
of 131 and 121 bp). After the first round of amplificationsupport this scenario, thereby further substantiating the
consisting of 25 cycles, 5 ml of this reaction was addednotion of a rapid turnover of productively infected cells
into triplicate nested reactions which were cycled 11, 17,in vivo, and clarifying the constitution of HIV-1 mRNA
or 22 rounds. The secondary reaction in which the signalsplicing patterns observed in HIV-infected persons.
was in the optimal linear range of amplification (as com-
pared to a standard dilution curve) was subsequently
MATERIALS AND METHODS used to estimate MS HIV mRNA copy-number in the
specimen (see below). This assay detects small HIV-1Nucleic acid preparation
mRNAs giving rise to Tat, Vif, Vpr, Rev, and Nef proteins.
Total cellular RNA and DNA were extracted from
PBMC specimens using TRI Reagent (Molecular Re- Amplification of GAPDH mRNA
search Center, Inc., Cincinnati, OH) according to the in-
To monitor the recovery of intact PBMC RNA from dif-structions from the supplier. Additionally, isolated RNA
ferent PBMC specimens and the uniform efficiency ofpreparations were treated for 1 hr with 100 U of RNase-
each reverse transcription reaction, a 189-bp glyceralde-free DNase (Boehringer Mannheim) in the presence of 50
hyde-3-phosphate dehydrogenase (GAPDH) mRNA-spe-U of placental RNase inhibitor (Boehringer Mannheim),
cific fragment was also amplified from each random-extracted with phenol-chloroform, and precipitated with
primed cDNA preparation. These reactions were cycledethanol.
for 20 rounds between 94 (1 min) and 677 (2 min) with
conditions otherwise as described above, and utilizedcDNA synthesis
the primers 5*-TGG TAT CGT GGA AGG ACT CAT GAC-
3* (sense) and 5*-ATG CCA GTG AGC TTC CCG TTCTwo micrograms of total DNase-treated PBMC RNA in
20 ml of water was heated for 5 min at 807, transferred AGC-3* (antisense).
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Controls, RNA standards and quantitation of well with our earlier observations on some AZT-treated
patients (Saksela et al., 1994) as well as with data re-amplification products
cently reported by Bagnarelli et al. (1996).
Each set of reverse transcription reactions included a
The observed change in MS/US ratio was caused by
control tube with no RNA which was subsequently used
the considerably smaller reduction in the expression of
for US- and MS-specific PCR reactions as a control for
US mRNA as compared to MS mRNA. In fact, in some
lack of contamination. In addition, every set of experi-
patients little or no decrease in US mRNA was observed
ments included a control RNA from PBMCs of an HIV-
at 1 week after treatment, although a significant drop in
negative donor. To provide standards for quantitation of
plasma viremia was evident in all patients at this point
the absolute HIV mRNA copy-numbers in the specimens,
(Table 1). This observation may reflect the trafficking of
all experiments also included a panel of 10 PBMC RNAs
lymphocytes (infected or not) from tissues into the circu-
with twofold serial dilutions of in vitro-transcribed US and
lation or could also be due to HIV genomic RNA associ-
MS RNA templates (Saksela et al., 1994) ranging from
ated with uninfected or nonproductively infected PBMCs
64 to 100,000 copies/mg of HIV-negative PBMC RNA. Ten
(see Discussion).
microliters of each PCR reaction was analyzed by elec-
A week of effective antiretroviral therapy (Table 1) can
trophoresis in 8% acrylamide:bisacrylamide (19:1) gels
be expected to cause a significant decrease in the rela-
in 11 TBE (90 mM Tris –borate, 1 mM EDTA), and the
tive number of cells which have been infected during the
intensities of the radiolabeled amplification products in
preceding few days. In light of available kinetic data from
the dried gels were quantitated using a PhosphorImager
studies in cell culture, the observed shift in HIV mRNA
(Molecular Dynamics, Inc., Sunnyvale, CA). The specific
splicing pattern after therapy therefore suggests that in
signals corresponding to the US and MS HIV mRNA-
a steady-state situation, this pattern directly reflects the
specific fragments (the value from an identical area
proportion of cells infected at various times before the
above the specific amplification signal in each lane was
analysis. The change in the HIV mRNA splicing pattern
subtracted) were normalized based on the specific
from the early MS mRNA-predominated pattern to the
GAPDH amplification signals from the same cDNA prep-
subsequent relative overexpression of US mRNA takes
arations, and used to calculate the absolute HIV mRNA
place within 12–48 hr of infection in vitro. To examine
copy-numbers in the specimens by comparing these sig-
the kinetics of the splicing shift induced by antiretroviral
nals with those of the HIV RNA standards analyzed in
therapy in vivo, HIV mRNA expression after initiation of
parallel. In addition, every assay included an aliquot of a
drug therapy was analyzed in greater detail in two pa-
common HIV-infected PBMC preparation. The interassay
tients (105 and 1302) from whom frequently collected
variation in the derived mRNA copy-numbers from re-
PBMC specimens were available.
peated analyses of this specimen was less than 25%.
Expression of HIV US and MS mRNA in PBMCs col-
Threshold of linear amplification of unspliced (US) and
lected from these two patients before treatment and at
multiply spliced (MS) HIV-1 mRNAs is 100 copies per
every 6–12 hr during the first 3 days of therapy is shown
microgram of total PBMC RNA.
in Fig. 2. In both cases, a substantial decrease in the
expression of MS mRNA was observed during this pe-
RESULTS
riod, with much of this reduction occurring between 12
and 48 hr after initiation of therapy (from 4271/mg to 651/Paired PBMC samples collected before and 1 week
after treatment with a HIV protease inhibitor or combina- mg in 105, and from 2701/mg to 823/mg in 1302). By con-
trast, no apparent decrease in HIV US mRNA was ob-tion therapy were selected from nine patients involved
in published and ongoing studies on dynamics of HIV-1 served during this period. These results are in good
agreement with kinetic data on HIV mRNA splicing duringinfection and efficacy of antiviral therapies (Perelson et
al., 1996; Table 1). Total RNA was extracted from PBMCs viral life-cycle in vitro (Kim et al., 1989; Klotman et al.,
1991; Michael et al., 1991; Pomerantz et al., 1990) andand subjected to quantitative RT-PCR to measure the
expression of US and MS mRNAs as described under thus suggest that the marked reduction in HIV MS mRNA
expression in vivo following administration of potent anti-Materials and Methods. Figure 1 shows the absolute
copy-numbers of US and MS mRNAs (per mg of PBMC viral drugs is due to a rapidly developing loss of cells in
an early postintegration phase of HIV life-cycle.RNA) in these specimens, and also displays as a bar
diagram the ratio of MS/US mRNA in each patient before
and after 7 days of drug therapy. As can be seen, regard- DISCUSSION
less of the overall level of HIV mRNA expression, in each
case a significant change in MS/US ratio was observed, The availability of novel potent antiretroviral drugs
have enabled us to perform an analysis of HIV mRNAsuch that this ratio decreased on average to 34% of its
pretreatment value. These results suggest that a change expression akin to an in vivo ‘‘pulse–chase experiment.’’
As predicted by in vitro studies on the regulation of HIVin HIV mRNA splicing pattern is a consistent conse-
quence of potent antiretroviral drug therapy and agree mRNA splicing during viral life-cycle (Kim et al., 1989;
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TABLE 1
Summary of the Treatment Modality, Base-Line Values, and the Effect of 7 Days of Therapy on Plasma Viral Load of the Study Patients
Base-line values
Plasma virions after
CD4 cells Plasma virions 7 days of therapy
Patient Treatment/total daily dose (/mm3) (1103/ml)a (1103/ml)a
2 –3 Nelfinavir/1000 mg 269 50 2.5
2 –18 Nelfinavir/3000 mg 334 64 5.9
2 –26 Nelfinavir/3000 mg 458 58 8.1
1302 Indinavir, 3TC, AZT/2400 mg, 300 mg, 600 mg 227 3166 52
102 Ritonavir/1200 mg 16 294 55
103 Ritonavir/1200 mg 408 12 0.7
104 Ritonavir/1200 mg 2 52 8.0
105 Ritonavir/1200 mg 11 643 85
107 Ritonavir/1200 mg 412 77 8.0
a Each virion contains two RNA copies.
Klotman et al., 1991; Michael et al., 1991; Pomerantz et late-stage splicing pattern due to the halt of new PBMCs
entering the pool of productively infected cells.al., 1990; Ranki et al., 1994), as well as recent insights
into the dynamics of HIV infection in vivo (Ho et al., 1995; Curiously, in some patients (such as 105) US HIV
mRNA decreased slower than what one would expectPerelson et al., 1996; Wei et al., 1995), a rapid change in
HIV mRNA splicing was observed in the drug-treated based on the drop in their plasma viral loads. As men-
tioned above, it could be that upon decreasing viral loadpatients. These data suggest that the early loss in MS
mRNA is caused by a change from an early-stage to a in the body, more lymphocytes (including infected cells
FIG. 1. The absolute copy numbers of HIV-1 unspliced (US) and multiply spliced (MS) mRNAs (per microgram of total PBMC RNA) and a bar
diagram of their ratio before and 7 days after the therapy in each of the nine study subjects.
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FIG. 2. Dynamics of HIV-1 splicing pattern in two study subjects during the first 3 days of therapy. Their PBMC HIV-1 unspliced (US; *ii/home2/
milesgrsym/8point/gs170,l(3,0) and multiply spliced ii/home2/milesgrsym/8point/gs172,l(3,0) mRNA expression is shown as copies per microgram
of total cellular RNA on a log scale. The MS/US mRNA ratio is presented at 12-hr intervals. (0) Not detected.
with a late-stage mRNA splicing pattern) enter the circu- uli, as reported after influenza vaccination (O’Brien et al.,
1995; Staprans et al., 1995) or IL-2 administration (Kovacslation thus providing an additional source of US mRNA.
However, and alternative explanation for this observation et al., 1995) could result in an increase of cells which are
in an early phase of infection, manifesting as a relativecould be that the decay of US mRNA might be partially
masked by the presence of genomic HIV RNA in the overexpression of MS mRNA. On the other hand, it is
possible that when HIV infection is spreading relativelyPBMC RNA preparations. Such ‘‘treatment-resistant’’ ge-
nomic RNA could be derived from viral particles stuck to unimpeded, as might be the case in severely immunode-
ficient patients, many more susceptible CD4/ cells arethe surface of PBMCs and survived through the fraction-
ation and washing of these cells. More interestingly (and already infected, resulting in a fewer number of newly
infected cells and thus a relative overexpression of USperhaps more likely) significant numbers of HIV genomes
mRNA. However, although such factors could cause al-might be present in resting T cells as preintegration com-
terations in the HIV mRNA splicing pattern, our data doplexes frozen in the viral life-cycle between entry and
not support a hypothesis that differential splicing wouldintegration (Bukrinsky et al., 1991; Chun et al., 1995; Ste-
be an actively regulated process involved in determiningvenson et al., 1990; Zack et al., 1990). Although such
the productivity of HIV-infection and the rate of disease‘‘preintegration latency’’ is probably relatively short-lived,
progression.it could give rise to an artifactually slow decay rate of
The present results suggest that examination of HIVUS mRNA in the present analysis. However, such unac-
MS/US mRNA ratio as an indicator of population dynam-counted sources of US HIV mRNA signal (if they exist in
ics of HIV-infected cells in vivo could be useful. By provid-significant amounts) are not likely to challenge the pres-
ing an almost instantaneous measure of the acute antivi-ent conclusions which are based on the prominent fall
ral potency of a drug regimen, monitoring of the earlyin MS HIV mRNA levels occurring during the first 48 hr
decrease in MS HIV mRNA expression might be usedof therapy without any accompanying decrease in the
as an additional molecular virological tool in developingexpression of US HIV mRNA.
and optimizing pharmacological agents to block HIV in-Besides supporting the current dynamic model of HIV
fection. In addition, more detailed analyses of the expres-infection (Ho et al., 1995; Perelson et al., 1996; Wei et
sion of differentially spliced HIV mRNAs in PBMCs andal., 1995), the present results suggest that HIV mRNA
other sites of HIV replication in the body might offersplicing in PBMCs in vivo is mainly determined by the
further insights into the dynamics of HIV infection in vivo.proportion of cells in different phases of infection. Situa-
tions apart from antiretroviral therapy that could result in ACKNOWLEDGMENTS
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